Physician profile
Veronica Eberhart
NPI 1073902094
$5,955.25
in general payments reported to CMS, 2019-2025
24 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 89% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $714 · 2022: $783 · 2023: $1,424 · 2024: $1,692 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,458.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,313.21 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $833.10 | 2021-2025 | Lifevest |
| Pfizer INC. | $616.94 | 2021-2025 | |
| Amgen INC. | $524.53 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $516.82 | 2022-2025 | Verquvo, Capvaxive, Winrevair |
| Boston Scientific Corporation | $396.40 | 2021-2025 | Watchman Flx, Watchman Access System, Farapulse |
| Astrazeneca Pharmaceuticals LP | $322.68 | 2021-2025 | Wainua, Farxiga |
| Novo Nordisk INC | $264.37 | 2021-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $249.18 | 2022-2025 | |
| Abiomed | $150.06 | 2024-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $125.25 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $101.53 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $95.51 | 2021-2025 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $81.06 | 2024-2025 | Amvuttra |
| Bridgebio Pharma, INC. | $69.31 | 2025 | Attruby |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $47.57 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.26 | 2021-2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $37.17 | 2023-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $32.68 | 2024 | Camzyos, Eliquis |
| Abbott Laboratories | $30.52 | 2023 | Cardiomems |
| Esperion Therapeutics, INC. | $29.56 | 2021-2024 | Nexletol |
| Amarin Pharma, INC. | $29.49 | 2021 | |
| Edwards Lifesciences Corporation | $24.51 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Philips North America LLC | $16.54 | 2024 | (5044) Mcot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Eberhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.